A blinded-endpoint, randomized controlled trial of Sanyrene with natural active ingredient for prophylaxis of radiation dermatitis in patients receiving radiotherapy

Table 3 Univariate and multivariate analysis for grade 2 skin toxicity

Variables	Univariate			Multivariate
Variables	HR	95%CI	P	HR	95%CI	P
BMI(kg/m²)	1.074	0.978–1.179	0.134
Total dose (Gy)	1.041	1.012–1.071	0.005	1.034	1.005–1.063	0.019
Treatment Group (Sanyrene vs. Control intervention)	0.231	0.116–0.458	< 0.001	0.247	0.124–0.493	< 0.001
Age (> 50 vs. ≤50)	1.117	0.617–2.023	0.714
Sex (female vs. male)	0.588	0.325–1.066	0.080
Smoke (yes vs. no)	1.448	0.350–5.987	0.609
Drink (yes vs. no)	3.038	0.937–9.855	0.064
ECOG (1 vs. 0)	0.660	0.359–1.211	0.180
Tumor (HNC vs. BC)	1.731	0.942–3.178	0.077
RT (VMAT vs. 3D-CRT)	2.001	1.060–3.779	0.032
CCRT(yes vs. no)	1.411	0.655–3.040	0.379

HNC, head and neck cancer; BC, breast cancer; 3D-CRT, 3-dimensional conformal radiation therapy; VMAT, volumetric modulated arc radiation therapy; CCRT, Concurrent chemotherapy

ISSN: 1748-717X